Other Clinical Trial - Camrelizumab Plus Pyrotinib Plus Chemotherapy in

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Active, not recruiting	`NCT05008783` - A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma	Phase 3
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Recruiting	`NCT03421288` - Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness	Phase 2
Completed	`NCT03196232` - Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer	Phase 2
Terminated	`NCT03511222` - Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors	Phase 1
Completed	`NCT02891447` - Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer	Phase 2
Completed	`NCT02864381` - Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Terminated	`NCT04032704` - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT03615326` - Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)	Phase 3
Completed	`NCT02830594` - Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer	Phase 2
Completed	`NCT02539225` - A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Recruiting	`NCT06038578` - A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer	Phase 2
Completed	`NCT04808791` - iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2
Recruiting	`NCT04581473` - Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection	Phase 1/Phase 2
Completed	`NCT00515411` - Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma	Phase 2
Recruiting	`NCT06206278` - Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma	Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2

NCT number	NCT05111444
Study type	Interventional
Source	Fudan University
Contact	Zhe Zhang, PHD
Phone	8621-64175590
Email	zhangzhe2010fduscc@gmail.com
Status	Not yet recruiting
Phase	Phase 2
Start date	December 31, 2021
Completion date	June 30, 2024

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms